Table 1 Baseline clinical and pharmacological characteristics of the study patients
|  | Non-Diabetic (n = 2181) | Good-control DM (n = 291) | Poor-control DM (n = 412) | P-value* | P-value†| P-value‡ |
|---|---|---|---|---|---|---|
Age (year) | 57.4 ± 10.8 | 59.9 ± 9.9 | 58.0 ± 9.8 | <0.0001 | 0.27 | 0.009 |
Male sex | 1653 (75.8) | 165 (56.7) | 203 (49.3) | <0.0001 | <0.0001 | 0.07 |
Hypertension | 1006 (46.1) | 172 (59.1) | 262 (63.6) | <0.0001 | <0.0001 | 0.35 |
Hyperlipidemia | 1318 (61.5) | 224 (77.8) | 328 (79.6) | <0.0001 | <0.0001 | 0.58 |
Current smoking | 1026 (47.0) | 79 (27.1) | 106 (25.7) | <0.0001 | <0.0001 | 0.86 |
Family history of CAD | 502 (23.1) | 63 (22.1) | 89 (21.6) | 0.77 | 0.45 | 0.78 |
BMI (kg/m2) | 27.3 ± 4.25 | 28.3 ± 4.1 | 28.2 ± 4.5 | <0.0001 | < 0.0001 | 0.85 |
WC (cm) | 99.4 ± 9.7 | 101.9 ± 9.0 | 102.3 ± 10.1 | <0.0001 | < 0.0001 | 0.61 |
EF < 30% | 68 (4.3) | 7 (3.5) | 17 (5.9) | 0.71 | 0.18 | 0.21 |
Medications | ||||||
Insulin | 0 (0) | 17 (6.0) | 69 (17.0) | <0.0001 | <0.0001 | <0.0001 |
OHA | 0 (0) | 84 (28.9) | 171 (41.5) | <0.0001 | <0.0001 | 0.001 |
ACEIs/ARBs | 1295 (59.4) | 180 (61.9) | 288 (69.9) | 0.35 | <0.0001 | 0.04 |
Statins | 1849 (84.8) | 255 (87.6) | 362 (87.9) | 0.121 | 0.06 | 0.912 |
Beta-blockers | 1915 (87.8) | 244 (83.8) | 355 (86.2) | 0.11 | 0.55 | 0.34 |